You are here

Live cell and HCS assays to quantify production of cardiomyocytes from stem cells

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R42HL086076-02
Agency Tracking Number: HL086076
Amount: $676,969.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: 2007
Award Year: 2007
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
VALA SCIENCES, INC. 3030 BUNKER HILL STREET
SAN DIEGO, CA 92109
United States
DUNS: 612181532
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PATRICK MCDONOUGH
 (858) 581-6275
 PMCDONOUGH@VALASCIENCES.COM
Business Contact
 TINA HUTH
Phone: (619) 210-3265
Email: THUTH@RNDBS.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Heart failure is a leading cause of mortality in modern society, and is the result from the death of cardiac myocytes. Contractile function of failing hearts can be restored by injecting the heart with embryonic stem cell-derived cardiac myocytes (ESCMs) which integrate into the host tissue. To facilitate production of ESCMs, high throughput screening systems are needed that can quantify ESCM production. The proposed research will develop an instrument that will utilizes live cell and high content screening (HCS) techniques to quantify the occurrence of ESCMs for stem cells cultured in 96-well dishes. The system will record intracellular calcium transients from ESCM cultures, which are a hallmark of differentiated cardiac myocytes. The system will feature electrode and controller assemblies that interface to commercial high content microscopy workstations (e.g., the Beckman IC100 and the Amersham Incell 1000) and will discriminate cells based on expression of fluorescent transgenes. Staining reagents and software for automated image analysis will also be developed to quantify the cellular expression and organization of cardiac-specific structures (myofibrils) and proteins (SERCA2). The system will enable testing of candidate chemicals for their ability to influence differentiation of ESCMs and provide a platform for conducting chemical genomic studies of the differentiation process. We will develop an instrument that will help researchers produce heart cells from embryonic stem cells. Heart cells produced in this manner can potentially be used to treat heart disease.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government